Literature DB >> 20081552

Neurological sequelae of 2009 influenza A (H1N1) in children: a case series observed during a pandemic.

Sirine A Baltagi1, Michael Shoykhet, Kathryn Felmet, Patrick M Kochanek, Michael J Bell.   

Abstract

OBJECTIVE: To outline a series of cases demonstrating neurologic complications in children with Influenza infection. The ongoing 2009 influenza A (H1N1) presents significant challenges to the field of pediatric critical care and requires increased awareness of new presentations and sequelae of infection. Since World Health Organization declared a H1N1 pandemic, much attention has been focused on its respiratory manifestations of the illness, but limited information regarding neurologic complications has been reported.
DESIGN: Case series.
SETTING: Pediatric intensive care unit of a tertiary care medical facility. PATIENTS: Four children admitted to the pediatric intensive care unit between March and November 2009 at the Children's Hospital of Pittsburgh with altered mental status and influenza infection.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The clinical course was extracted by chart review and is summarized. All children demonstrated a coryzal prodrome, fever, and altered level of consciousness at admission, and one child presented with clinical seizures. Diagnostic studies performed to establish a diagnosis are summarized. All children had abnormal electroencephalograms early in their intensive care unit course and 50% had abnormal imaging studies. All children survived but 50% had neurologic deficits at hospital discharge.
CONCLUSION: We conclude that 2009 influenza A (H1N1) can cause significant acute and residual neurologic sequelae. Clinicians should consider Influenza within a comprehensive differential diagnosis in children with unexplained mental status changes during periods of pandemic influenza.

Entities:  

Mesh:

Year:  2010        PMID: 20081552     DOI: 10.1097/PCC.0b013e3181cf4652

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  39 in total

Review 1.  Neurologic and muscular complications of the 2009 influenza A (H1N1) pandemic.

Authors:  Larry E Davis
Journal:  Curr Neurol Neurosci Rep       Date:  2010-11       Impact factor: 5.081

2.  Critically ill children during the 2009-2010 influenza pandemic in the United States.

Authors:  Adrienne G Randolph; Frances Vaughn; Ryan Sullivan; Lewis Rubinson; B Taylor Thompson; Grace Yoon; Elizabeth Smoot; Todd W Rice; Laura L Loftis; Mark Helfaer; Allan Doctor; Matthew Paden; Heidi Flori; Christopher Babbitt; Ana Lia Graciano; Rainer Gedeit; Ronald C Sanders; John S Giuliano; Jerry Zimmerman; Timothy M Uyeki
Journal:  Pediatrics       Date:  2011-11-07       Impact factor: 7.124

3.  Clinical reasoning: an unexpected diagnosis in a 4-month-old infant with lethargy and H1N1 influenza.

Authors:  Ann E Hyslop; Brian S Droker; Laura A Jansen
Journal:  Neurology       Date:  2011-05-03       Impact factor: 9.910

4.  Neurologic complications of influenza A(H1N1)pdm09: surveillance in 6 pediatric hospitals.

Authors:  Gulam Khandaker; Yvonne Zurynski; Jim Buttery; Helen Marshall; Peter C Richmond; Russell C Dale; Jenny Royle; Michael Gold; Tom Snelling; Bruce Whitehead; Cheryl Jones; Leon Heron; Mary McCaskill; Kristine Macartney; Elizabeth J Elliott; Robert Booy
Journal:  Neurology       Date:  2012-09-19       Impact factor: 9.910

5.  Comparison of clinical presentation of respiratory tract infections in H1N1/09-positive and H1N1/09-negative patients.

Authors:  Pierre-Alex Crisinel; Constance Barazzone; Laurent Kaiser; Arnaud G L'Huillier; Jean Taguebue; Noémie Wagner; Cristina Delcò; Claire-Anne Siegrist; Klara M Posfay-Barbe
Journal:  Eur J Pediatr       Date:  2011-06-15       Impact factor: 3.183

6.  HSV encephalitis-induced anti-NMDAR encephalitis in a 67-year-old woman: report of a case and review of the literature.

Authors:  Nicholas A Morris; Tamara B Kaplan; Jenny Linnoila; Tracey Cho
Journal:  J Neurovirol       Date:  2015-07-03       Impact factor: 2.643

Review 7.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.

Authors:  Josep Dalmau; Eric Lancaster; Eugenia Martinez-Hernandez; Myrna R Rosenfeld; Rita Balice-Gordon
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

8.  Neurology of the H1N1 pandemic in Singapore: a nationwide case series of children and adults.

Authors:  Asha Prerna; Jocelyn Y X Lim; Natalie W H Tan; Mas Suhaila Isa; Helen May-Lin Oh; Norazieda Yassin; Chian-Yong Low; Derrick W S Chan; Chia-Yin Chong; Yee-Sin Leo; Angela Li-Ping Chow; Paul Ananth Tambyah; Kevin Tan
Journal:  J Neurovirol       Date:  2015-04-28       Impact factor: 2.643

9.  Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype?

Authors:  Jianqiang Ye; Erin M Sorrell; Yibin Cai; Hongxia Shao; Kemin Xu; Lindomar Pena; Danielle Hickman; Haichen Song; Matthew Angel; Rafael A Medina; Balaji Manicassamy; Adolfo Garcia-Sastre; Daniel R Perez
Journal:  PLoS Pathog       Date:  2010-10-14       Impact factor: 6.823

Review 10.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.